US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

DOGWOOD THERAPEUTICS INC

1.98

-0.1000-4.81%

Pre-market: 2.010.0300+1.52%04:01 EDT

Volume:85.05K

Turnover:174.65K

Market Cap:65.93M

PE:-0.28

High:2.22

Open:2.01

Low:1.94

Close:2.08

52wk High:9.50

52wk Low:1.94

Shares:33.30M

Float Shares:7.00M

Volume Ratio:0.67

T/O Rate:1.22%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-7.1350

EPS(LYR):-7.1350

ROE:-49.23%

ROA:-18.95%

PB:0.88

PE(LYR):-0.28

Loading ...

Overview Company News Filings

Dogwood Therapeutics Inc - Expects Top-Line Results in Q3 2026

THOMSON REUTERS

BRIEF-Dogwood Therapeutics Inc - Enters Equity Distribution Agreement With Northland Securities - SEC Filing

Dogwood Therapeutics Inc - to Sell Shares Worth up to $8.56 Mln - SEC Filing

THOMSON REUTERS

Dogwood Therapeutics Inc. held special shareholder meeting

Dogwood Therapeutics Q3 EPS USD -8.2

Dogwood Therapeutics Enrolls First 100 Patients in Halneuron Phase 2b Neuropathy Trial

Analysts Are Bullish on These Healthcare Stocks: Altimmune (ALT), Dogwood Therapeutics (DWTX)

BRIEF-Dogwood Therapeutics Q3 EPS USD -8.2

Dogwood Therapeutics reports Q3 net loss of $15.7 million

Dogwood Therapeutics Inc expected to post a loss of $1.22 a share - Earnings Preview

Dogwood Therapeutics Inc. Announces Date for Upcoming Special Stockholders Meeting

Dogwood to present on Halneuron pain research program

Dogwood Therapeutics Announces Phase 2b Clinical Trial of Halneuron® for Chemotherapy-Induced Neuropathic Pain

Dogwood files to sell 28.04M shares of common stock for holders

Dogwood price target raised to $12 from $10 at H.C. Wainwright

Dogwood Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $12 From $10

THOMSON REUTERS

Dogwood Therapeutics Inc. Publishes Investor Presentation Highlighting Progress in Halneuron® Phase 2b Study for Chemotherapy-Induced Neuropathic Pain and New SP16 Cancer Pain License

Top Premarket Gainers

MT Newswires Live

Dogwood secures royalty free license to develop, commercialize SP16

Dogwood Therapeutics Inc - Secures Royalty-Free License for SP16 in All-Stock Deal With Serpin Pharma

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/DWTX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DWTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DWTX\",,,,,undefined,":{"symbol":"DWTX","market":"US","secType":"STK","nameCN":"DOGWOOD THERAPEUTICS INC","latestPrice":1.98,"timestamp":1774641600000,"preClose":2.08,"halted":0,"volume":85051,"hourTrading":{"tag":"盘前","latestPrice":2.01,"preClose":1.98,"latestTime":"04:01 EDT","volume":10,"amount":20.099999999999998,"timestamp":1774857662768,"change":0.03,"changeRate":0.015152,"amplitude":0},"delay":0,"changeRate":-0.04807692307692312,"floatShares":6995900,"shares":33295600,"eps":-7.13499,"marketStatus":"Pre-Mkt","change":-0.1,"latestTime":"03-30 04:18:50 EDT","open":2.01,"high":2.215,"low":1.9431,"amount":174652.44963259998,"amplitude":0.130721,"askPrice":2.96,"askSize":100,"bidPrice":1.98,"bidSize":38,"shortable":3,"etf":0,"ttmEps":-7.13499,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1774877400000},"marketStatusCode":1,"adr":0,"listingDate":1608181200000,"exchange":"NASDAQ","adjPreClose":1.98,"preHourTrading":{"tag":"盘前","latestPrice":2.01,"preClose":1.98,"latestTime":"04:01 EDT","volume":10,"amount":20.099999999999998,"timestamp":1774857662768,"change":0.03,"changeRate":0.015152,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":1.98,"preClose":1.98,"latestTime":"19:02 EDT","volume":168,"amount":333.84,"timestamp":1774652545446,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6723507592149446},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DWTX\",,,,,undefined,":{"symbol":"DWTX","floatShares":6995900,"roa":"-18.95%","roe":"-49.23%","lyrEps":-7.13499,"volumeRatio":0.6723507592149446,"shares":33295600,"dividePrice":0,"high":2.215,"amplitude":0.130721,"preClose":2.08,"low":1.9431,"week52Low":1.9431,"pbRate":"0.88","week52High":9.5,"institutionHeld":0,"latestPrice":1.98,"committee":-0.449275,"eps":-7.13499,"divideRate":0,"volume":85051,"delay":0,"ttmEps":-7.13499,"open":2.01,"prevYearClose":4.16,"prevWeekClose":3,"prevMonthClose":2.85,"prevQuarterClose":4.16,"fiveDayClose":3,"twentyDayClose":2.85,"sixtyDayClose":4.14},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DWTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-18","symbol":"DWTX","fiscalQuarterEnding":"2025/12","expectedEps":-1.22,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1773806400000,"reportTimeType":"pre","actualEps":-0.26},{"market":"US","date":"2025-11-06","symbol":"DWTX","fiscalQuarterEnding":"2025/09","expectedEps":-1.23,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"pre","actualEps":-8.2},{"market":"US","date":"2025-08-13","symbol":"DWTX","fiscalQuarterEnding":"2025/06","expectedEps":-1.26,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"pre","actualEps":-1.99},{"market":"US","date":"2025-05-08","symbol":"DWTX","fiscalQuarterEnding":"2025/03","expectedEps":-0.77,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"pre","actualEps":-4.21},{"market":"US","date":"2025-03-31","symbol":"DWTX","fiscalQuarterEnding":"2024/12","expectedEps":-1.49,"name":null,"time":"","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"","actualEps":-6.29}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DWTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DWTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1745467200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/DWTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"DWTX","date":"2026-03-27","current":-0.277506,"percent":0.239011,"low":-5.30677,"twenty":-2.43626,"median":-0.591133,"eighty":-0.413812,"high":-0.31572,"avg":-1.166941,"sd":1.079229,"marketCap":69475230},"quantilePoints":[{"date":"2024-10-11","current":-0.88829,"twenty":-0.871777,"median":-0.847007,"eighty":-0.822237,"marketCap":4156676},{"date":"2024-10-18","current":-1.14168,"twenty":-1.243599,"median":-1.14168,"eighty":-0.919038,"marketCap":5342394},{"date":"2024-10-25","current":-1.352393,"twenty":-1.244175,"median":-1.155915,"eighty":-1.05342,"marketCap":6328406},{"date":"2024-10-31","current":-1.184386,"twenty":-1.27834,"median":-1.174407,"eighty":-1.098974,"marketCap":5542234},{"date":"2024-11-08","current":-1.035557,"twenty":-1.27834,"median":-1.184386,"eighty":-1.098974,"marketCap":5928592},{"date":"2024-11-15","current":-0.74467,"twenty":-1.269799,"median":-1.17156,"eighty":-0.88829,"marketCap":4263257},{"date":"2024-11-22","current":-0.6306,"twenty":-1.266952,"median":-1.124597,"eighty":-0.74467,"marketCap":3610202},{"date":"2024-11-29","current":-0.558465,"twenty":-1.264674,"median":-1.042032,"eighty":-0.629204,"marketCap":3197227},{"date":"2024-12-06","current":-0.532869,"twenty":-1.261826,"median":-0.94447,"eighty":-0.591959,"marketCap":3050687},{"date":"2024-12-13","current":-0.560792,"twenty":-1.247591,"median":-0.805175,"eighty":-0.586099,"marketCap":3210548},{"date":"2024-12-20","current":-0.53985,"twenty":-1.196344,"median":-0.717909,"eighty":-0.564981,"marketCap":3090652},{"date":"2024-12-27","current":-0.609658,"twenty":-1.179261,"median":-0.679489,"eighty":-0.564515,"marketCap":3490306},{"date":"2025-01-03","current":-0.584061,"twenty":-1.174695,"median":-0.665504,"eighty":-0.565461,"marketCap":3343766},{"date":"2025-01-10","current":-0.553811,"twenty":-1.172405,"median":-0.646888,"eighty":-0.565454,"marketCap":3170583},{"date":"2025-01-17","current":-0.449099,"twenty":-1.164457,"median":-0.623619,"eighty":-0.558465,"marketCap":2571103},{"date":"2025-01-24","current":-3.106463,"twenty":-1.170151,"median":-0.6306,"eighty":-0.558465,"marketCap":17784576},{"date":"2025-01-31","current":-2.969173,"twenty":-1.244175,"median":-0.653869,"eighty":-0.558465,"marketCap":16998591},{"date":"2025-02-07","current":-2.748114,"twenty":-1.269799,"median":-0.667831,"eighty":-0.560792,"marketCap":15733022},{"date":"2025-02-14","current":-1.561376,"twenty":-1.386529,"median":-0.691147,"eighty":-0.563119,"marketCap":8938914},{"date":"2025-02-21","current":-1.36824,"twenty":-1.406654,"median":-0.738827,"eighty":-0.564981,"marketCap":7833206},{"date":"2025-02-28","current":-1.095988,"twenty":-1.389852,"median":-0.805175,"eighty":-0.565476,"marketCap":6274558},{"date":"2025-03-07","current":-1.030834,"twenty":-1.384928,"median":-0.926984,"eighty":-0.569177,"marketCap":5901548},{"date":"2025-03-14","current":-1.798723,"twenty":-1.448286,"median":-1.000651,"eighty":-0.577546,"marketCap":10297735},{"date":"2025-03-21","current":-1.056947,"twenty":-1.431015,"median":-0.999453,"eighty":-0.58313,"marketCap":13053004},{"date":"2025-03-28","current":-0.925409,"twenty":-1.421838,"median":-0.979572,"eighty":-0.584992,"marketCap":11428545},{"date":"2025-04-04","current":-0.646858,"twenty":-1.406654,"median":-0.930825,"eighty":-0.586099,"marketCap":7988515},{"date":"2025-04-11","current":-0.317141,"twenty":-1.389852,"median":-0.88829,"eighty":-0.58313,"marketCap":3916603},{"date":"2025-04-17","current":-0.402359,"twenty":-1.385328,"median":-0.805724,"eighty":-0.565469,"marketCap":4969023},{"date":"2025-04-25","current":-0.61055,"twenty":-1.374755,"median":-0.785584,"eighty":-0.565469,"marketCap":7540127},{"date":"2025-05-02","current":-0.578189,"twenty":-1.358732,"median":-0.74467,"eighty":-0.568254,"marketCap":7140474},{"date":"2025-05-09","current":-0.374989,"twenty":-1.330168,"median":-0.724741,"eighty":-0.565469,"marketCap":8714743},{"date":"2025-05-16","current":-0.451467,"twenty":-1.293145,"median":-0.691147,"eighty":-0.558465,"marketCap":10492092},{"date":"2025-05-23","current":-0.435842,"twenty":-1.273215,"median":-0.667831,"eighty":-0.549157,"marketCap":10128978},{"date":"2025-05-30","current":-0.43502,"twenty":-1.26866,"median":-0.661674,"eighty":-0.542709,"marketCap":10109867},{"date":"2025-06-06","current":-0.424679,"twenty":-1.265813,"median":-0.656935,"eighty":-0.524492,"marketCap":9335860},{"date":"2025-06-13","current":-0.450325,"twenty":-1.262965,"median":-0.649201,"eighty":-0.469065,"marketCap":9899643},{"date":"2025-06-20","current":-0.417289,"twenty":-1.258453,"median":-0.635392,"eighty":-0.460532,"marketCap":9173414},{"date":"2025-06-27","current":-0.414681,"twenty":-1.246626,"median":-0.62674,"eighty":-0.450325,"marketCap":9116080},{"date":"2025-07-03","current":-0.417289,"twenty":-1.244175,"median":-0.623619,"eighty":-0.448744,"marketCap":9173414},{"date":"2025-07-11","current":-0.433807,"twenty":-1.191392,"median":-0.616057,"eighty":-0.435137,"marketCap":9536528},{"date":"2025-07-18","current":-0.413812,"twenty":-1.184386,"median":-0.61055,"eighty":-0.430908,"marketCap":9096969},{"date":"2025-07-25","current":-0.411204,"twenty":-1.175845,"median":-0.606188,"eighty":-0.428591,"marketCap":9039635},{"date":"2025-08-01","current":-0.420332,"twenty":-1.175104,"median":-0.602999,"eighty":-0.424679,"marketCap":9240303},{"date":"2025-08-08","current":-0.425287,"twenty":-1.172969,"median":-0.594948,"eighty":-0.422505,"marketCap":9349238},{"date":"2025-08-15","current":-0.380049,"twenty":-1.170151,"median":-0.588976,"eighty":-0.421636,"marketCap":9402749},{"date":"2025-08-22","current":-0.381594,"twenty":-1.165796,"median":-0.584643,"eighty":-0.419028,"marketCap":9440972},{"date":"2025-08-29","current":-0.370394,"twenty":-1.14168,"median":-0.579408,"eighty":-0.417298,"marketCap":9163858},{"date":"2025-09-05","current":-0.386229,"twenty":-1.128014,"median":-0.578189,"eighty":-0.417289,"marketCap":9555640},{"date":"2025-09-12","current":-0.378257,"twenty":-1.116602,"median":-0.565465,"eighty":-0.414688,"marketCap":9358411},{"date":"2025-09-19","current":-0.371892,"twenty":-1.1021,"median":-0.560792,"eighty":-0.413812,"marketCap":9200934},{"date":"2025-09-26","current":-0.394726,"twenty":-1.096585,"median":-0.556138,"eighty":-0.410856,"marketCap":9765864},{"date":"2025-10-03","current":-0.495918,"twenty":-1.064755,"median":-0.553811,"eighty":-0.413012,"marketCap":12269441},{"date":"2025-10-10","current":-0.519049,"twenty":-1.045015,"median":-0.552647,"eighty":-0.413742,"marketCap":12841707},{"date":"2025-10-17","current":-0.55705,"twenty":-1.036852,"median":-0.55705,"eighty":-0.413812,"marketCap":13781903},{"date":"2025-10-24","current":-0.520902,"twenty":-1.035502,"median":-0.552647,"eighty":-0.413812,"marketCap":12887570},{"date":"2025-10-31","current":-0.61637,"twenty":-1.031765,"median":-0.55705,"eighty":-0.414507,"marketCap":15249527},{"date":"2025-11-07","current":-0.481974,"twenty":-1.007156,"median":-0.555431,"eighty":-0.414681,"marketCap":11924442},{"date":"2025-11-14","current":-0.327725,"twenty":-1.000768,"median":-0.549157,"eighty":-0.413742,"marketCap":12520664},{"date":"2025-11-21","current":-0.357136,"twenty":-0.998735,"median":-0.545565,"eighty":-0.409242,"marketCap":13644313},{"date":"2025-11-28","current":-0.391355,"twenty":-0.987046,"median":-0.544503,"eighty":-0.403493,"marketCap":14951645},{"date":"2025-12-05","current":-0.368541,"twenty":-0.971236,"median":-0.53985,"eighty":-0.398837,"marketCap":14080014},{"date":"2025-12-12","current":-4.995522,"twenty":-0.987046,"median":-0.53985,"eighty":-0.39658,"marketCap":190852899},{"date":"2025-12-19","current":-4.746524,"twenty":-1.032696,"median":-0.544503,"eighty":-0.398429,"marketCap":181339982},{"date":"2025-12-26","current":-3.40816,"twenty":-1.050981,"median":-0.545001,"eighty":-0.398837,"marketCap":130208053},{"date":"2026-01-02","current":-3.236974,"twenty":-1.111477,"median":-0.549157,"eighty":-0.39905,"marketCap":123667922},{"date":"2026-01-09","current":-2.451074,"twenty":-1.16928,"median":-0.552647,"eighty":-0.399948,"marketCap":93642777},{"date":"2026-01-16","current":-2.351299,"twenty":-1.182678,"median":-0.557977,"eighty":-0.400578,"marketCap":89830899},{"date":"2026-01-23","current":-2.578032,"twenty":-1.247239,"median":-0.558465,"eighty":-0.402359,"marketCap":98493164},{"date":"2026-01-30","current":-2.435274,"twenty":-1.269799,"median":-0.561956,"eighty":-0.404249,"marketCap":93039145},{"date":"2026-02-06","current":-2.662007,"twenty":-1.36824,"median":-0.565484,"eighty":-0.407726,"marketCap":101701410},{"date":"2026-02-13","current":-2.536044,"twenty":-1.420694,"median":-0.572344,"eighty":-0.408596,"marketCap":96889041},{"date":"2026-02-20","current":-2.536071,"twenty":-1.540898,"median":-0.574661,"eighty":-0.409242,"marketCap":96890059},{"date":"2026-02-27","current":-2.405345,"twenty":-1.831766,"median":-0.578189,"eighty":-0.409453,"marketCap":91895726},{"date":"2026-03-06","current":-2.492496,"twenty":-2.234293,"median":-0.579338,"eighty":-0.410856,"marketCap":95225281},{"date":"2026-03-13","current":-2.623221,"twenty":-2.344581,"median":-0.583582,"eighty":-0.413012,"marketCap":100219614},{"date":"2026-03-20","current":-2.638773,"twenty":-2.411331,"median":-0.585772,"eighty":-0.413742,"marketCap":90397426},{"date":"2026-03-27","current":-2.028037,"twenty":-2.43626,"median":-0.591133,"eighty":-0.413812,"marketCap":69475230}],"updateTime":1774830850145},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DWTX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2593436535","title":"Dogwood Therapeutics Inc - Expects Top-Line Results in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2593436535","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593436535?lang=en_us&edition=fundamental","pubTime":"2025-12-22 23:15","pubTimestamp":1766416500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nTUA1GJWL4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DWTX","BK4139"],"gpt_icon":0},{"id":"2587378447","title":"BRIEF-Dogwood Therapeutics Inc - Enters Equity Distribution Agreement With Northland Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2587378447","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587378447?lang=en_us&edition=fundamental","pubTime":"2025-11-29 04:33","pubTimestamp":1764362038,"startTime":"0","endTime":"0","summary":"BRIEF-Dogwood Therapeutics Inc - Enters Equity Distribution Agreement With Northland Securities - SEC FilingDogwood Therapeutics Inc DWTX.O:DOGWOOD THERAPEUTICS INC - ENTERS EQUITY DISTRIBUTION AGREEMENT WITH NORTHLAND SECURITIES - SEC FILINGDOGWOOD THERAPEUTICS INC - TO SELL SHARES WORTH UP TO $8.56 MILLION - SEC FILINGSource text: [ID:n0001104659-25-116865]Further company coverage: DWTX.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nFWN3X40L8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"gpt_icon":0},{"id":"2587734046","title":"Dogwood Therapeutics Inc - to Sell Shares Worth up to $8.56 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2587734046","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587734046?lang=en_us&edition=fundamental","pubTime":"2025-11-29 03:19","pubTimestamp":1764357556,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nFWN3X40L8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DWTX","BK4139"],"gpt_icon":0},{"id":"2585140483","title":"Dogwood Therapeutics Inc. held special shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2585140483","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585140483?lang=en_us&edition=fundamental","pubTime":"2025-11-22 02:02","pubTimestamp":1763748125,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Inc. held a special meeting of stockholders on November 21, 2025. Stockholders approved the Second Amended and Restated Equity Incentive Plan, which increases the number of shares reserved for issuance. Approval was also granted for the potential issuance of common stock upon conversion of both the Series A and Series A-2 Non-Voting Convertible Preferred Stock. The adjournment of the special meeting to a later date or dates, if necessary or appropriate, was also approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and E","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDL2bX39h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"gpt_icon":0},{"id":"2584099926","title":"Dogwood Therapeutics Q3 EPS USD -8.2","url":"https://stock-news.laohu8.com/highlight/detail?id=2584099926","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584099926?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:55","pubTimestamp":1763571340,"startTime":"0","endTime":"0","summary":"Nov 06 (Reuters) - Dogwood Therapeutics Q3 net income USD -15.7 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 06-NOV-202513:05:00.123 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD2ZBlq9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"gpt_icon":0},{"id":"2582736445","title":"Dogwood Therapeutics Enrolls First 100 Patients in Halneuron Phase 2b Neuropathy Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2582736445","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582736445?lang=en_us&edition=fundamental","pubTime":"2025-11-11 21:45","pubTimestamp":1762868717,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Inc. announced the enrollment of the first 100 patients in its ongoing Phase 2b HALT-CINP clinical trial evaluating Halneuron for chemotherapy-induced neuropathic pain . The study is assessing the safety and effectiveness of Halneuron compared to placebo in cancer patients with neuropathy resulting from previous platinum or taxane-based chemotherapy. Participants receive eight subcutaneous doses over 14 days, with follow-up at 28 days. The primary endpoint is the change in weekly average daily pain intensity scores from baseline to week four. An interim sample size analysis is scheduled for the fourth quarter of 2025, and final trial data are expected by mid-2026. Results from the study have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpr","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251111:nNDLCf3wS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DWTX"],"gpt_icon":0},{"id":"2582656358","title":"Analysts Are Bullish on These Healthcare Stocks: Altimmune (ALT), Dogwood Therapeutics (DWTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582656358","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582656358?lang=en_us&edition=fundamental","pubTime":"2025-11-08 23:40","pubTimestamp":1762616412,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Altimmune (ALT – Research Report) and Dogwood Therap...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-altimmune-alt-dogwood-therapeutics-dwtx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-altimmune-alt-dogwood-therapeutics-dwtx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ALT","LU0029874061.USD","BK4137","LABU","BK4585","XBI","BK4581","BK4588","HCSG","LU1878469433.USD","BK4599","XLV","LU0128526141.USD","DWTX","BK4112"],"gpt_icon":0},{"id":"2581096224","title":"BRIEF-Dogwood Therapeutics Q3 EPS USD -8.2","url":"https://stock-news.laohu8.com/highlight/detail?id=2581096224","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581096224?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:45","pubTimestamp":1762436745,"startTime":"0","endTime":"0","summary":"BRIEF-Dogwood Therapeutics Q3 EPS USD -8.2\n\n\nNov 06 (Reuters) - Dogwood Therapeutics Q3 net income USD -15.7 million.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nPLXF50854:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DWTX"],"gpt_icon":0},{"id":"2581909621","title":"Dogwood Therapeutics reports Q3 net loss of $15.7 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581909621","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581909621?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:45","pubTimestamp":1762436720,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Inc. reported a net loss attributable to common stockholders of $15.7 million, or $8.20 per basic and diluted share, for the third quarter of 2025, compared to a net loss of $2.3 million, or $2.05 per share, for the same period in 2024. Research and development expenses increased to $14.5 million from $0.5 million, mainly due to $12.0 million in acquired in-process research and development related to the SP16 licensing agreement, as well as higher clinical trial costs. General and administrative expenses decreased to $1.3 million from $1.8 million, primarily due to lower legal and accounting fees. The company reported cash on hand of $10.1 million, expected to fund operations through the first quarter of 2026. Key business developments included enrollment of 100 patients in the Halneuron Phase 2b trial, acquisition of an exclusive license for SP16 as a cancer-related pain treatment, and progress toward a prespecified interim analysis of the Halneuron trial in the f","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL2nbGfw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B64PRP62.GBP","BK4585","IE00B3QW5Z07.USD","LU2210149790.SGD","NDAQ","IE00BGHQF748.EUR","BK4139","IE00BKPKM429.USD","BK4112","DWTX","LU0314104364.USD","LU2210150020.SGD","LU2095319765.USD"],"gpt_icon":0},{"id":"2580732076","title":"Dogwood Therapeutics Inc  expected to post a loss of $1.22 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2580732076","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580732076?lang=en_us&edition=fundamental","pubTime":"2025-11-04 21:40","pubTimestamp":1762263605,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Inc  expected to post a loss of $1.22 a share - Earnings Preview Dogwood Therapeutics Inc DWTX.OQ DWTX.O is expected to  show no change in quarterly revenue when it reports  resul","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nL8N3WG1RM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"gpt_icon":0},{"id":"2574970771","title":"Dogwood Therapeutics Inc. Announces Date for Upcoming Special Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2574970771","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574970771?lang=en_us&edition=fundamental","pubTime":"2025-10-09 05:18","pubTimestamp":1759958299,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Inc. has announced that it will hold a special meeting of stockholders on November 21, 2025. The meeting will be conducted virtually. Further details regarding the matters to be considered at the meeting are available in the company's proxy materials.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 08, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nNDL1PrfP8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"gpt_icon":0},{"id":"2573963561","title":"Dogwood to present on Halneuron pain research program","url":"https://stock-news.laohu8.com/highlight/detail?id=2573963561","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573963561?lang=en_us&edition=fundamental","pubTime":"2025-10-07 21:30","pubTimestamp":1759843811,"startTime":"0","endTime":"0","summary":"Dogwood (DWTX) Therapeutics announced that its Chief Medical Officer will present an overview of the Halneuron pain management research program at ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dogwood-to-present-on-halneuron-pain-research-program-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dogwood-to-present-on-halneuron-pain-research-program-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DWTX","BK4139"],"gpt_icon":0},{"id":"2573624950","title":"Dogwood Therapeutics Announces Phase 2b Clinical Trial of Halneuron® for Chemotherapy-Induced Neuropathic Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2573624950","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573624950?lang=en_us&edition=fundamental","pubTime":"2025-10-07 20:45","pubTimestamp":1759841123,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Inc. , a development-stage biotechnology company, has announced that its Chief Medical Officer, Dr. Michael Gendreau, will present an overview of the Halneuron  pain management research program at the upcoming 19th Annual Pain Therapeutics Summit on October 14, 2025. Halneuron is currently being evaluated in a Phase 2b clinical trial  at 25 sites across the United States. The study aims to assess the safety and efficacy of low dose injectable Halneuron in reducing chemotherapy induced neuropathic pain  in cancer patients. To date, more than 700 patients have participated in clinical studies with tetrodotoxin for various indications. Results from the current Phase 2b study have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nNDL3prpWM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DWTX","BK4007","BK4588","BK4585","BK4547","SAVA"],"gpt_icon":0},{"id":"2572555797","title":"Dogwood files to sell 28.04M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2572555797","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572555797?lang=en_us&edition=fundamental","pubTime":"2025-10-02 04:20","pubTimestamp":1759350032,"startTime":"0","endTime":"0","summary":"16:15 EDT Dogwood (DWTX) files to sell 28.04M shares of common stock for holders Published first on TheFly – the ultimate source for real-time, mar...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dogwood-files-to-sell-28-04m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dogwood-files-to-sell-28-04m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DWTX","BK4139"],"gpt_icon":0},{"id":"2571345720","title":"Dogwood price target raised to $12 from $10 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2571345720","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571345720?lang=en_us&edition=fundamental","pubTime":"2025-09-30 18:15","pubTimestamp":1759227345,"startTime":"0","endTime":"0","summary":"H.C. Wainwright raised the firm’s price target on Dogwood (DWTX) to $12 from $10 and keeps a Buy rating on the shares after the company announced a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dogwood-price-target-raised-to-12-from-10-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dogwood-price-target-raised-to-12-from-10-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DWTX","BK4139"],"gpt_icon":0},{"id":"2571345354","title":"Dogwood Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $12 From $10","url":"https://stock-news.laohu8.com/highlight/detail?id=2571345354","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571345354?lang=en_us&edition=fundamental","pubTime":"2025-09-30 18:04","pubTimestamp":1759226680,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nAZN4LHAXX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DWTX"],"gpt_icon":0},{"id":"2571335676","title":"Dogwood Therapeutics Inc. Publishes Investor Presentation Highlighting Progress in Halneuron® Phase 2b Study for Chemotherapy-Induced Neuropathic Pain and New SP16 Cancer Pain License","url":"https://stock-news.laohu8.com/highlight/detail?id=2571335676","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571335676?lang=en_us&edition=fundamental","pubTime":"2025-09-29 20:35","pubTimestamp":1759149311,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Inc. Publishes Investor Presentation Highlighting Progress in Halneuron Phase 2b Study for Chemotherapy-Induced Neuropathic Pain and New SP16 Cancer Pain License. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief on September 29, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nNDL86zFlg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"gpt_icon":0},{"id":"2571338359","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2571338359","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571338359?lang=en_us&edition=fundamental","pubTime":"2025-09-29 19:53","pubTimestamp":1759146790,"startTime":"0","endTime":"0","summary":"JFB Construction  shares were almost 94% higher pre-bell Monday after the company said late Friday that it has secured a private placement deal with American Ventures for up to $44 million in equity financing.Dogwood Therapeutics  stock was up 60% after the company said it has secured an exclusive worldwide, royalty license to develop and commercialize Serpin Pharma's SP16 as a treatment for cancer-related pain.Steakholder Foods  shares were 46% higher following a muted session.Merus  stock was up 38% on a pending $8 billion takeover by Genmab .Bicara Therapeutics  shares were 20% higher, adding to Friday's gains.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0889565916.HKD","BK4139","JFB","BK4129","BK4212","BCAX","GMAB","MRUS","STKH","LU0320765992.SGD","LU0109394709.USD","DWTX"],"gpt_icon":0},{"id":"2571387714","title":"Dogwood secures royalty free license to develop, commercialize SP16","url":"https://stock-news.laohu8.com/highlight/detail?id=2571387714","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571387714?lang=en_us&edition=fundamental","pubTime":"2025-09-29 19:20","pubTimestamp":1759144842,"startTime":"0","endTime":"0","summary":"Dogwood (DWTX) Therapeutics announced that in an all-stock transaction, it has secured a royalty free, global license to develop Serpin Pharma’s in...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dogwood-secures-royalty-free-license-to-develop-commercialize-sp16-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dogwood-secures-royalty-free-license-to-develop-commercialize-sp16-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DWTX","BK4139"],"gpt_icon":0},{"id":"2571387133","title":"Dogwood Therapeutics Inc - Secures Royalty-Free License for SP16 in All-Stock Deal With Serpin Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2571387133","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571387133?lang=en_us&edition=fundamental","pubTime":"2025-09-29 19:16","pubTimestamp":1759144586,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nFWN3VG0DX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DWTX"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":40,"code":"91000000","status":"200"}]}}